Source MS Trust: Lemtrada (alemtuzumab) should be restricted to people with highly active relapsing-remitting MS according to a review carried out by the European Medicines Agency's (EMA) drug safety committee.
Highly active relapsing-remitting MS covers people who continue to have relapses despite taking at least one disease-modifying drug (DMD) or if MS is worsening rapidly with at least two disabling relapses in a year and MRI scans show new MS activity. In addition, Lemtrada must no longer be used in people with certain heart, circulation or bleeding disorders or in people who have auto-immune disorders other than MS.
The recommendations also include new measures to identify and treat problems that may occur after having a Lemtrada infusion. Read on.